Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 137 clinical trials
None
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

: Endocrine carcinoma of pancreas and digestive tract.) (closed to accrual) Neuroendocrine carcinoma including carcinoid of the lung (closed to accrual 12/19/2017) Pheochromocytoma

lung cancer
extrahepatic cholangiocarcinoma
estimated creatinine clearance
pituitary
hysterectomy
  • 6055 views
  • 05 Dec, 2021
  • 819 locations
None
Safety Tolerability Pharmacokinetics and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors

The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and early clinical activity of INCB099280 in participants with select solid tumors

solid tumors
solid tumour
  • 1 views
  • 11 Sep, 2021
  • 18 locations
None
Phase 1/2 Study of the Highly-selective RET Inhibitor Pralsetinib (BLU-667) in Patients With Thyroid Cancer Non-Small Cell Lung Cancer and Other Advanced Solid Tumors

This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic activity of pralsetinib (BLU-667) administered orally in patients with medullary thyroid cancer, RET-altered NSCLC and other RET-altered solid tumors.

lung cancer
antineoplastic agents
nucleic acid
cancer
solid tumor
  • 1646 views
  • 18 Nov, 2021
  • 93 locations
None
TAS-102 in Extrapulmonary Neuroendocrine Carcinoma

metastatic colorectal cancer (mCRC). Recently, a study evaluating TAS-102 showed a case of complete remission of high-grade NEC. Given the safety profile of TAS-102 and the remarkable single agent activity

  • 7 views
  • 23 Jan, 2021
  • 1 location
None
Second-line Therapy for Patients With Progressive Poorly Differentiated Extra-pulmonary Neuroendocrine Carcinoma

There is currently no standard treatment beyond first-line etoposide/platinum-based chemotherapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma

  • 0 views
  • 12 Mar, 2021
  • 4 locations
None
Chidamide Plus Etoposide and Cisplatin/Carboplatin as First-line Treatment for Extrapulmonary Neuroendocrine Carcinoma

neuroendocrine carcinoma.

measurable disease
platelet count
carboplatin
neutrophil count
etoposide
  • 0 views
  • 12 Nov, 2021
  • 3 locations
None
Efficacy of Neoadjuvant Chemotherapy in Terms of DFS in Patients With Localized Digestive Neuroendocrine Carcinomas

NEONEC is a single-phase, phase II study evaluating the efficacy of the 12-month neoadjuvant chemotherapy in patients with locally differentiated digestive NEC. The recommended chemotherapy is

metastasis
positron emission tomography
immunomodulator
carboplatin
who 2017
  • 0 views
  • 22 Jun, 2021
  • 9 locations
None
Ph I/II Trial of Systemic VSV-IFN -NIS and Pembrolizumab in Refractory NSCLC and NEC

expansion portion will use one-sample binomial designs to assess the efficacy of the combination in patients with refractory NSCLC or NEC. The optimal dose (RP2D) determined in the dose escalation portion

carcinoma
measurable disease
immune checkpoint inhibitor
cancer treatment
stage iv non-small cell lung cancer
  • 2 views
  • 20 Oct, 2021
  • 1 location
None
Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma

This study will test the use of comprehensive ablative radiation therapy (CART), with and without the immunotherapy drug avelumab, in people with Merkel cell carcinoma (MCC) that has progressed after treatment and cannot be removed with surgery. The study researchers want to find out whether CART works better when is …

  • 0 views
  • 21 Mar, 2021
  • 7 locations
None
Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma

This is a single arm trial of participants with Merkel cell carcinoma receiving a combination of lenvatinib plus pembrolizumab.

  • 0 views
  • 22 Sep, 2021
  • 1 location